|
2009 |
November |
Co-promotion agreement with Lundbeck for Ebixa®, a treatment for altzheimer’s disease |
| August |
Mami Ai®, a probiotic for kids, selected as one of the top brands in China |
| June |
Amosartan®, an antihypertensive combination drug of Amodipine and Losartan, launched |
| May |
Co-promotion agreement with GSK in respiration-allergy area |
|
2008 |
May |
Hanmi-Crystal genomics Strategic alliance |
| February |
US FDA approval for Ceftriaxone API |
|
2007 |
August |
KGMP approval on Cephalosporin Finished Product manufacturing facility in Pyongtaek . |
| July |
First launching of anti-obesity drug ‘Slimmer®’(sibutramine mesilate) |
|
2006 |
December |
Successful development of Mexibufen Syrup, using alternative salt |
| July |
Published clinical study for Amodipin® |
|
2004 |
June |
Patent of Amodipine, a new salt form of Amlodipine, granted |
| January |
Successful development of Fedipine table, a 24hr controlled-release formulation of Nifedipine |
|
2003 |
November |
Registered as Hanmi Photographic Museum from government |
| October |
Hanmi Pharm. marking its 30-year foundation day |
| March |
Changes into Hanmi Pharmaceutical Co., Ltd |
| February |
Designation of Hanmi’s central research labs as ‘ICE GMP Technology Center’ |
|
2002 |
June |
Establishment of Hanmi Foundation of Art & Culture |
| June |
Completion of Hanmi GMP plant in Beijing |
|
2001 |
February |
Development of oral antifungal agent ‘Itra tablet’ for 2nd in the world |
|
2000 |
September |
Successful development of oral anticancer drug paclitaxel |
